Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 1 15Phase NA 5Phase 1/2 5Phase 3 4Phase EARLY_PHASE1 2Phase 2/3 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 6CNS 5Breast 4Lymphoid 3Gynecologic 3Genitourinary 3Dermatologic 3Sarcoma 2Other hematologic neoplasm 2Thoracic 1Myeloid 1Head & Neck 1Classical hematology 1

Conditions

Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Ependymoma 1Breast Neoplasms 1Astrocytoma 1

Interventions

Magnetic Resonance Spectroscopy 6pembrolizumab 3Specimen Handling 3Radiotherapy 3Oncolytic Virotherapy 3Nivolumab 3Irinotecan 3Cyclophosphamide 3X-Rays 2Temozolomide 2Etoposide 2Doxorubicin 2Biopsy 2Bevacizumab 2trastuzumab biosimilar HLX02 1sodium thiosulfate 1romiplostim 1pertuzumab 1perflutren 1palbociclib 1olaparib 1niraparib 1montelukast 1glucarpidase 1gamma-Glutamyl Hydrolase 1fluorodopa F 18 1eribulin 1entrectinib 1entacapone 1cobimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Biopsy × Sarcoma × Clear all
NCT01165632 2025-09-02

Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma

Mayo Clinic

Phase EARLY_PHASE1 Completed
24 enrolled
CNSSarcoma

Astrocytoma, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Glioma, Subependymal, Gliosarcoma

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡